Alnylam Pharmaceuticals (ALNY) Cash from Financing Activities (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Cash from Financing Activities data on file, last reported at $15.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 65.9% year-over-year to $15.7 million; the trailing twelve-month figure through Mar 2026 stood at -$335.6 million (down 207.78% YoY), and the FY2025 full-year result was -$305.2 million, down 203.75% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $15.7 million, down from $45.3 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $297.0 million in Q3 2022 and bottomed at -$448.3 million in Q3 2025.
• The 5-year median for Cash from Financing Activities is $45.3 million (2025), against an average of $35.4 million.
• The widest annual swing landed in 2024, when Cash from Financing Activities soared 210.08%; it then sank 536.33% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at $63.4 million in 2022, then plunged by 38.16% to $39.2 million in 2023, then slipped by 20.98% to $31.0 million in 2024, then jumped by 46.2% to $45.3 million in 2025, then slumped by 65.32% to $15.7 million in 2026.
• The last three Cash from Financing Activities figures came in at $15.7 million (Q1 2026), $45.3 million (Q4 2025), and -$448.3 million (Q3 2025), per Business Quant data.

Peer Comparison